The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
American Chemical Society (ACS)
2017
|
| Online Access: | http://hdl.handle.net/1721.1/108537 https://orcid.org/0000-0002-2693-4982 |
| _version_ | 1826217932912328704 |
|---|---|
| author | Suntharalingam, Kogularamanan Johnstone, Timothy Lippard, Stephen J. |
| author2 | Massachusetts Institute of Technology. Department of Chemistry |
| author_facet | Massachusetts Institute of Technology. Department of Chemistry Suntharalingam, Kogularamanan Johnstone, Timothy Lippard, Stephen J. |
| author_sort | Suntharalingam, Kogularamanan |
| collection | MIT |
| description | The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes. Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations, including supramolecular self-assembled structures, proteins, peptides, metal–organic frameworks, and coordination polymers, will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive. |
| first_indexed | 2024-09-23T17:11:21Z |
| format | Article |
| id | mit-1721.1/108537 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T17:11:21Z |
| publishDate | 2017 |
| publisher | American Chemical Society (ACS) |
| record_format | dspace |
| spelling | mit-1721.1/1085372022-10-03T11:03:11Z The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs Suntharalingam, Kogularamanan Johnstone, Timothy Lippard, Stephen J. Massachusetts Institute of Technology. Department of Chemistry Johnstone, Timothy Lippard, Stephen J. The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes. Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations, including supramolecular self-assembled structures, proteins, peptides, metal–organic frameworks, and coordination polymers, will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive. National Cancer Institute (U.S.) (CA034992) 2017-05-01T17:28:58Z 2017-05-01T17:28:58Z 2016-02 2015-10 Article http://purl.org/eprint/type/JournalArticle 0009-2665 1520-6890 http://hdl.handle.net/1721.1/108537 Johnstone, Timothy C.; Suntharalingam, Kogularamanan and Lippard, Stephen J. “The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.” Chemical Reviews 116, no. 5 (March 2016): 3436–3486. © 2016 American Chemical Society https://orcid.org/0000-0002-2693-4982 en_US http://dx.doi.org/10.1021/acs.chemrev.5b00597 Chemical Reviews Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf American Chemical Society (ACS) PMC |
| spellingShingle | Suntharalingam, Kogularamanan Johnstone, Timothy Lippard, Stephen J. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs |
| title | The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs |
| title_full | The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs |
| title_fullStr | The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs |
| title_full_unstemmed | The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs |
| title_short | The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs |
| title_sort | next generation of platinum drugs targeted pt ii agents nanoparticle delivery and pt iv prodrugs |
| url | http://hdl.handle.net/1721.1/108537 https://orcid.org/0000-0002-2693-4982 |
| work_keys_str_mv | AT suntharalingamkogularamanan thenextgenerationofplatinumdrugstargetedptiiagentsnanoparticledeliveryandptivprodrugs AT johnstonetimothy thenextgenerationofplatinumdrugstargetedptiiagentsnanoparticledeliveryandptivprodrugs AT lippardstephenj thenextgenerationofplatinumdrugstargetedptiiagentsnanoparticledeliveryandptivprodrugs AT suntharalingamkogularamanan nextgenerationofplatinumdrugstargetedptiiagentsnanoparticledeliveryandptivprodrugs AT johnstonetimothy nextgenerationofplatinumdrugstargetedptiiagentsnanoparticledeliveryandptivprodrugs AT lippardstephenj nextgenerationofplatinumdrugstargetedptiiagentsnanoparticledeliveryandptivprodrugs |